Van Zyl Engelbrecht (M.Sc (Med)) serves as the Head of Country Operations for the United Kingdom within AstraZeneca’s Rare Disease Research Unit (Alexion Pharmaceuticals). He is deeply committed to advancing innovative therapeutic approaches and ensuring that patients gain timely access to transformative treatments.
In his role, Van Zyl works at the intersection of scientific, regulatory, and operational disciplines, maintaining direct engagement with the complexities of clinical development. He takes great pride in the meaningful contributions he and his team make toward the successful delivery of compliant, high‑quality, and often highly complex clinical trials. His leadership is grounded in scientific rigor, operational excellence, and an unwavering focus on improving patient outcomes.